These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31243887)

  • 1. The use of induction therapy in liver transplantation is highly variable and is associated with posttransplant outcomes.
    Bittermann T; Hubbard RA; Lewis JD; Goldberg DS
    Am J Transplant; 2019 Dec; 19(12):3319-3327. PubMed ID: 31243887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.
    Berger SP; Sommerer C; Witzke O; Tedesco H; Chadban S; Mulgaonkar S; Qazi Y; de Fijter JW; Oppenheimer F; Cruzado JM; Watarai Y; Massari P; Legendre C; Citterio F; Henry M; Srinivas TR; Vincenti F; Gutierrez MPH; Marti AM; Bernhardt P; Pascual J;
    Am J Transplant; 2019 Nov; 19(11):3018-3034. PubMed ID: 31152476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed calcineurin inhibitor introduction and renal outcomes in liver transplant recipients receiving basiliximab induction.
    Lange NW; Salerno DM; Sammons CM; Jesudian AB; Verna EC; Brown RS
    Clin Transplant; 2018 Dec; 32(12):e13415. PubMed ID: 30276862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Alemtuzumab and Basiliximab Induction on Patient Survival and Time to Bronchiolitis Obliterans Syndrome in Double Lung Transplantation Recipients.
    Furuya Y; Jayarajan SN; Taghavi S; Cordova FC; Patel N; Shiose A; Leotta E; Criner GJ; Guy TS; Wheatley GH; Kaiser LR; Toyoda Y
    Am J Transplant; 2016 Aug; 16(8):2334-41. PubMed ID: 26833657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effectiveness and safety of antibody induction immunosuppression in a large cohort of United States pediatric liver transplant recipients.
    Wood P; Huang YS; Sanchez L; Kitt E; Abt PL; Bittermann T
    Am J Transplant; 2023 Jun; 23(6):794-804. PubMed ID: 36933831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal dose and type of immunosuppression in a national cohort of Australian liver, heart, and lung transplant recipients, 1984-2006.
    Na R; Laaksonen MA; Grulich AE; Webster AC; Meagher NS; McCaughan GW; Keogh AM; Vajdic CM
    Clin Transplant; 2015 Nov; 29(11):978-90. PubMed ID: 26278925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial.
    Saliba F; Duvoux C; Gugenheim J; Kamar N; Dharancy S; Salamé E; Neau-Cransac M; Durand F; Houssel-Debry P; Vanlemmens C; Pageaux G; Hardwigsen J; Eyraud D; Calmus Y; Di Giambattista F; Dumortier J; Conti F
    Am J Transplant; 2017 Jul; 17(7):1843-1852. PubMed ID: 28133906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-liver transplant renal dysfunction and association with post-transplant end-stage renal disease: A single-center examination of updated UNOS recommendations.
    Chauhan K; Azzi Y; Faddoul G; Liriano-Ward L; Chang P; Nadkarni G; Delaney V; Ames S; Debnath N; Singh N; Sehgal V; Di Boccardo G; Garzon F; Nair V; Kent R; Lerner S; Coca S; Shapiro R; Florman S; Schiano T; Menon MC
    Clin Transplant; 2018 Dec; 32(12):e13428. PubMed ID: 30338873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of liver transplantation for acute fatty liver disease of pregnancy.
    Kushner T; Tholey D; Dodge J; Saberi B; Schiano T; Terrault N
    Am J Transplant; 2019 Jul; 19(7):2101-2107. PubMed ID: 31017355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction Immunosuppression and Clinical Outcomes in Kidney Transplant Recipients Infected With Human Immunodeficiency Virus.
    Kucirka LM; Durand CM; Bae S; Avery RK; Locke JE; Orandi BJ; McAdams-DeMarco M; Grams ME; Segev DL
    Am J Transplant; 2016 Aug; 16(8):2368-76. PubMed ID: 27111897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of two different antithymocyte globulins used in induction therapy in kidney transplant recipients: A single-center experience.
    Styrc B; Sobolewski M; Chudek J; Kolonko A; Więcek A
    Clin Transplant; 2019 Oct; 33(10):e13680. PubMed ID: 31365162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive comparison of three different immunosuppressive regimens for liver transplant patients with hepatocellular carcinoma: steroid-free immunosuppression, induction immunosuppression and standard immunosuppression.
    Liu YY; Li CP; Huai MS; Fu XM; Cui Z; Fan LL; Zhang S; Liu Y; Ma J; Li G; Shen ZY
    PLoS One; 2015; 10(3):e0120939. PubMed ID: 25816221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alemtuzumab induction and belatacept maintenance in marginal pathology renal allografts.
    Sparkes T; Ravichandran B; Opara O; Ugarte R; Drachenberg CB; Philosophe B; Bromberg JS; Barth RN
    Clin Transplant; 2019 Jun; 33(6):e13531. PubMed ID: 30866104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of induction immunosuppression on patient survival in heart transplant recipients treated with tacrolimus and mycophenolic acid in the current allocation era.
    Amin AA; Araj FG; Ariyamuthu VK; Drazner MH; Ayvaci MUS; Mammen PPA; Mete M; Urey MA; Tanriover B
    Clin Transplant; 2019 Aug; 33(8):e13651. PubMed ID: 31230375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Everolimus-based Immunosuppression on Renal Function in Liver Transplant Recipients.
    Nogueras López F; Abellan Alfocea P; Ortega Suazo EJ; López Garrido MA; Becerra Massare A; Gila Medina AM; Redondo Cerezo E; Espinosa Aguilar MD
    Transplant Proc; 2020 Mar; 52(2):556-558. PubMed ID: 32035673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends of Immunosuppression and Outcomes Following Liver Transplantation: An Analysis of the United Network for Organ Sharing Registry.
    Cheng EY; Everly MJ
    Clin Transpl; 2014; ():13-26. PubMed ID: 26281123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction Therapy, Rejection, and Graft Outcomes in Pediatric and Adolescent Kidney Transplant Recipients.
    Mincham CM; Wong G; Teixeira-Pinto A; Kennedy S; Alexander S; Larkins N; Lim WH
    Transplantation; 2017 Sep; 101(9):2146-2151. PubMed ID: 28832451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of immunosuppression minimization and withdrawal early after liver transplantation.
    Shaked A; DesMarais MR; Kopetskie H; Feng S; Punch JD; Levitsky J; Reyes J; Klintmalm GB; Demetris AJ; Burrell BE; Priore A; Bridges ND; Sayre PH
    Am J Transplant; 2019 May; 19(5):1397-1409. PubMed ID: 30506630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of post-transplant diabetes mellitus on liver transplant outcomes.
    Lieber SR; Lee RA; Jiang Y; Reuter C; Watkins R; Szempruch K; Gerber DA; Desai CS; DeCherney GS; Barritt AS
    Clin Transplant; 2019 Jun; 33(6):e13554. PubMed ID: 30927288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential rates of ischemic cholangiopathy and graft survival associated with induction therapy in DCD liver transplantation.
    Halldorson JB; Bakthavatsalam R; Montenovo M; Dick A; Rayhill S; Perkins J; Reyes J
    Am J Transplant; 2015 Jan; 15(1):251-8. PubMed ID: 25534449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.